<?xml version='1.0' encoding='utf-8'?>
<document id="30911879"><sentence text="Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs." /><sentence text="Here we characterize and summarize the pharmacokinetic changes for metabolized drugs when drug-drug interactions and pharmacogenomic variance are observed" /><sentence text=" Following multiple dosing to steady-state, oral systemic concentration-time curves appear to follow a one-compartment body model, with a shorter rate limiting half-life, often significantly shorter than the single dose terminal half-life" /><sentence text=" This simplified disposition model at steady-state allows comparisons of measurable parameters (i" /><sentence text="e" /><sentence text=", area under the curve, half-life, maximum concentration and time to maximum concentration) following drug interaction or pharmacogenomic variant studies to be utilized to characterize whether a drug is low versus high hepatic extraction ratio, even without intravenous dosing" /><sentence text=" The characteristics of drugs based on the ratios of area under the curve, maximum concentration and half-life are identified with recognition that volume of distribution is essentially unchanged for drug interaction and pharmacogenomic variant studies where only metabolic outcomes are changed and transporters are not significantly involved" /><sentence text=" Comparison of maximum concentration changes following single dose interaction and pharmacogenomic variance studies may also identify the significance of intestinal first pass changes" /><sentence text=" The irrelevance of protein binding changes on pharmacodynamic outcomes following oral and intravenous dosing of low hepatic extraction ratio drugs, versus its relevance for high hepatic extraction ratio drugs is re-emphasized" /><sentence text="" /></document>